Nektar Therapeutics’ experimental immunotherapy bempegaldesleukin paired with Bristol Myers Squibb’s (BMS) blockbuster checkpoint inhibitor, Opdivo (nivolumab), did not shrink tumors, slow the growth of tumors or prolong survival rates for metastatic melanoma patients in a phase 3 trial in which the combo was compared to Opdivo alone.
Source: Drug Industry Daily